{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:38Z","timestamp":1792790198181,"version":"4.5.0"},"reference-count":41,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"OOO Firn M","award":["22\/05\/23"],"award-info":[{"award-number":["22\/05\/23"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are widespread human pathogens that establish chronic latent infections leading to recurrent episodes. Current treatments are limited, necessitating the development of novel antiviral strategies. This study aimed to assess the antiviral efficacy of novel topical formulations containing interferon alpha-2b (IFN \u03b1-2b) against HSV-1 and HSV-2. The formulations, Oftalmoferon\u00ae forte (eye drops) and Interferon Vaginal Tablets, demonstrated potent antiviral effects against HSV-1 and HSV-2 in Vero cells, respectively, with concentration-dependent inhibition of viral replication. Subsequently, their efficacy was tested in animal models: HSV-1 keratitis in the rabbit eye model and HSV-2 genital herpes in mice. Oftalmoferon\u00ae forte effectively treated HSV-1 keratitis, reducing clinical symptoms and ulcerations compared to virus control. Interferon Vaginal Tablets showed promising results in controlling HSV-2 genital herpes in mice, improving survival rates, reducing clinical signs, weight loss and viral replication. The novel IFN \u03b1-2b formulations exhibited significant antiviral activity against HSV infections in cell culture and animal models. These findings suggest the potential of these formulations as alternative treatments for HSV infections, particularly in cases resistant to current therapies. Further studies are warranted to optimize treatment regimens and assess clinical efficacy in humans.<\/jats:p>","DOI":"10.3390\/v16060989","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:10:28Z","timestamp":1718968228000},"page":"989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Topical Novel Formulations of Interferon \u03b1-2\u0432 Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7289-693X","authenticated-orcid":false,"given":"Anna","family":"Ivanina","sequence":"first","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Leneva","sequence":"additional","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9836-9620","authenticated-orcid":false,"given":"Irina","family":"Falynskova","sequence":"additional","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-9733","authenticated-orcid":false,"given":"Ekaterina","family":"Glubokova","sequence":"additional","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2096-5080","authenticated-orcid":false,"given":"Nadezhda","family":"Kartashova","sequence":"additional","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-3665","authenticated-orcid":false,"given":"Nadezda","family":"Pankova","sequence":"additional","affiliation":[{"name":"OOO Firn M, Biotech Company, 108804 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6565-6794","authenticated-orcid":false,"given":"Sergei","family":"Korovkin","sequence":"additional","affiliation":[{"name":"OOO Firn M, Biotech Company, 108804 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Svitich","sequence":"additional","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"ref_1","unstructured":"(2024, March 01). WHO, Herpes Simplex Virus. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/herpes-simplex-virus."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/21505594.2021.1982373","article-title":"Pathogenesis and virulence of herpes simplex virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Virulence"},{"key":"ref_3","first-page":"337","article-title":"Herpes Simplex Virus: Epidemiology, Diagnosis, and Treatment","volume":"55","author":"Cole","year":"2020","journal-title":"Nurs. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00006454-199402000-00030","article-title":"Recurrent ocular herpes simplex infection","volume":"13","author":"Balfour","year":"1994","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI136225","article-title":"Herpesvirus Latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1128\/JVI.01865-15","article-title":"Coinfections: Another Variable in the Herpesvirus Latency-Reactivation Dynamic","volume":"90","author":"Reese","year":"2016","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/ceo.13319","article-title":"Clinical translation of recommendations from randomized trials for management of herpes simplex virus keratitis","volume":"46","author":"Robaei","year":"2018","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_8","unstructured":"Rezaei, N. (2022). Encyclopedia of Infection and Immunity, Elsevier."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003226-200101000-00001","article-title":"Herpes simplex virus epidemiology and ocular importance","volume":"20","author":"Liesegang","year":"2001","journal-title":"Cornea"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/00002030-200108004-00011","article-title":"The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations","volume":"15","author":"Weiss","year":"2001","journal-title":"AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00007435-200104000-00001","article-title":"Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines","volume":"28","author":"Smith","year":"2001","journal-title":"Sex. Transm. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/340041","article-title":"Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988\u20131994","volume":"185","author":"Xu","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00007435-200101000-00011","article-title":"Herpes simplex virus type 2 seroepidemiology in Spain: Prevalence and seroconversion rate among sexually transmitted disease clinic attendees","volume":"28","author":"Varela","year":"2001","journal-title":"Sex. Transm. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-98-6-958","article-title":"Genital herpes simplex virus infections: Current concepts in diagnosis, therapy, and prevention","volume":"98","author":"Corey","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.1982.03330090015007","article-title":"The diagnosis and treatment of genital herpes","volume":"248","author":"Corey","year":"1982","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1055\/s-0042-116494","article-title":"Herpes genitalis: Diagnosis, treatment and prevention","volume":"76","author":"Sauerbrei","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.00245-20","article-title":"In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection","volume":"64","author":"Hopkins","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijos.2016.3","article-title":"New Strategies Against Drug Resistance to Herpes Simplex Virus","volume":"8","author":"Jiang","year":"2016","journal-title":"Int. J. Oral Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101300","DOI":"10.1016\/j.smim.2019.101300","article-title":"Global virus outbreaks: Interferons as 1st responders","volume":"43","author":"Wang","year":"2019","journal-title":"Semin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"Interferon induction and function at the mucosal surface","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.17116\/klinderma202221021214","article-title":"Interferon therapy of recurrent herpesvirus infections","volume":"21","author":"Khryanin","year":"2022","journal-title":"Russ. J. Clin. Dermatol. Venereol."},{"key":"ref_22","first-page":"76","article-title":"Ostrye respiratornye virusnye infektsii: Aktual\u2019nye voprosy diagnostiki, profilaktiki i lecheniya v praktike terapevta [Acute respiratory viral infections: Topical issues of diagnosis, prevention and treatment in therapeutic practice]","volume":"88","author":"Trukhan","year":"2016","journal-title":"Ter. Arkh."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1185\/030079907X226302","article-title":"Azelastine hydrochloride:a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability","volume":"23","author":"Bernstein","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0091-6749(89)90013-4","article-title":"The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites","volume":"83","author":"Casale","year":"1989","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1081-1206(10)63465-5","article-title":"Inhibition of leukotriene synthesis by azelastine","volume":"76","author":"Hamasaki","year":"1996","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.4049\/jimmunol.159.6.2932","article-title":"Suppression of TNF-\u03b1 secretion by azelastine in a rat mast (RBL-2H3) cell line","volume":"159","author":"Hide","year":"1997","journal-title":"J. Immunol."},{"key":"ref_27","first-page":"481","article-title":"Influence of the anti-allergic agent, azelastine, on tumor necrosis factor-alpha (TNF-\u03b1) secretion from cultured mouse mast cells","volume":"12","author":"Matsuo","year":"1998","journal-title":"In Vivo"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.37897\/RJPhP.2020.4.6","article-title":"Development of fast release foaming vaginal tablets with clotrimazole. II. The influence of the environmental conditions on preparation and stability","volume":"13","author":"Leucuta","year":"2020","journal-title":"Rom. J. Pharm. Pract."},{"key":"ref_29","first-page":"145","article-title":"The use of interferons 1 and 2 types in viral infections","volume":"58","author":"Ershov","year":"2013","journal-title":"Probl. Virol."},{"key":"ref_30","first-page":"54","article-title":"Viferon Suppositoria in Therapy of Relapsing Herpesvirus Infection in Women","volume":"54","author":"Vasilyev","year":"2009","journal-title":"Antibiot Khimioter=Antibiot. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1167\/iovs.02-1251","article-title":"In Vivo Antiviral Efficacy of a Dipeptide Acyclovir Prodrug, Val-Val-Acyclovir, against HSV-1 Epithelial and Stromal Keratitis in the Rabbit Eye Model","volume":"44","author":"Anand","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_32","first-page":"15","article-title":"Herpetic infection: Etiology, pathogenesis, clinic and diagnostics","volume":"3","author":"Zubritsky","year":"2009","journal-title":"J. GrGMU"},{"key":"ref_33","first-page":"119","article-title":"Herpes virus infection. Clinical and immunological features","volume":"3\u20134","author":"Dyudyun","year":"2015","journal-title":"Clin. Lect. DVKS J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.survophthal.2012.01.005","article-title":"Herpes simplex epithelial and stromal keratitis: An epidemiologic update","volume":"57","author":"Farooq","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"ref_35","first-page":"57","article-title":"Herpes simplex virus infections of the central nervous system: Encephalitis and meningitis, including Mollaret\u2019s","volume":"11","author":"Tyler","year":"2004","journal-title":"Herpes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2006.04.002","article-title":"Herpes simplex encephalitis: Adolescents and adults","volume":"71","author":"Whitley","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_37","first-page":"378","article-title":"Effect of exogenous interferon on herpetic keratitis in rabbits and monkeys","volume":"12","author":"Sugar","year":"1973","journal-title":"Investig. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Madavaraju, K., Koganti, R., Volety, I., Yadavalli, T., and Shukla, D. (2021). Herpes Simplex Virus Cell Entry Mechanisms: An Update. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.617578"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1462-5822.2004.00389.x","article-title":"Herpes Simplex Virus: Receptors and Ligands for Cell Entry","volume":"6","author":"Spear","year":"2004","journal-title":"Cell. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kutle, I., Dittrich, A., and Wirth, D. (2023). Mouse Models for Human Herpesviruses. Pathogens, 12.","DOI":"10.3390\/pathogens12070953"},{"key":"ref_41","first-page":"93","article-title":"Cytopathogenic effect in mice with herpes infection","volume":"6","author":"Baimatov","year":"2013","journal-title":"Proc. Orenbg. State Agrar. Univ."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:01:22Z","timestamp":1760108482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060989"],"URL":"https:\/\/doi.org\/10.3390\/v16060989","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]}}}